Genetically proxied inhibition of angiotensinogen synthesis is associated with lower cardiovascular risk

Human genetic evidence demonstrates that inhibiting hepatic angiotensinogen synthesis lowers blood pressure and significantly reduces the risk of coronary artery disease, stroke, and heart failure without raising major safety concerns, thereby supporting the potential of angiotensinogen inhibitors as effective cardiovascular therapies.

The Gist

The Big Picture: A "Genetic Crystal Ball" for Heart Medicine

Imagine you are a doctor trying to decide if a new, experimental medicine is safe and effective. Usually, you have to wait years for clinical trials to finish before you know the answer. But what if you could look into a "genetic crystal ball" to see what would happen if millions of people took this medicine for their entire lives?

That is exactly what this study did. The researchers looked at genetics to predict the future of a new type of blood pressure drug called an Angiotensinogen (AGT) inhibitor.

The Problem: The "Factory" That Never Stops

Your body has a system called the Renin-Angiotensin-Aldosterone System (RAAS). Think of this system as a thermostat for your blood pressure.

• The Factory: Your liver is a factory that produces a raw material called Angiotensinogen (AGT).
• The Chain Reaction: This raw material gets turned into a chemical that tightens your blood vessels, raising your blood pressure.
• The Current Fix: We already have drugs (like ACE inhibitors) that stop the machinery that processes this raw material. They work well, but they don't stop the factory from making the raw material in the first place.

The New Idea: What if we could shut down the factory itself? That's what these new RNA-based drugs (like Zilebesiran) try to do. They tell the liver, "Stop making AGT."

The Experiment: Using DNA as a Test Run

Since we can't wait 10 years for the final clinical trial results (which won't be ready until 2030), the researchers used Mendelian Randomization.

The Analogy: Imagine you want to know if a new diet causes weight loss. Instead of putting 1,000 people on the diet for a year, you look at 1,000 people who were born with a genetic mutation that naturally makes them eat less. If those people are naturally thinner, you know the diet works.

In this study, the researchers found people who naturally have lower levels of AGT because of their DNA. They treated these people as if they had been taking the new drug for their whole lives.

What They Found: The "Good News"

The genetic "test run" showed that shutting down the AGT factory is a huge win for heart health.

1. Lower Blood Pressure: Just like the new drugs do in early trials, the genetic "low AGT" people had lower blood pressure.
2. Fewer Heart Attacks and Strokes: Because their blood pressure was lower, they had a significantly lower risk of:
   • Coronary Artery Disease (clogged heart arteries).
   • Stroke (blocked or burst brain arteries).
   • Heart Failure (a tired, weak heart).
3. Better Brain Health: The study found that these people had less "wear and tear" on their brains (less small vessel disease), which is crucial for preventing dementia.
4. Better Heart Shape: Their hearts were less likely to become thick and stiff (a common problem in high blood pressure).

The Verdict: The new drug approach seems just as effective as the old, approved drugs, but it might be even better because it stops the problem at the source.

The "Bad News" (Safety Checks)

Every medicine has side effects. The researchers checked to see if turning off the AGT factory caused any disasters.

• The K-Potassium Issue: The main side effect was high potassium.
  • Analogy: Think of your body as a garden. The RAAS system is the sprinkler. If you turn off the sprinkler too much, the soil (your blood) gets too salty with potassium. This is a known side effect of blood pressure drugs, but usually, it's mild and manageable.
• The Liver Check: They worried that because the drug targets the liver, it might hurt the liver. The genetic data showed no major liver damage. There was one tiny blip in a liver enzyme, but it wasn't the kind that suggests real injury.
• Kidney Safety: Surprisingly, the "low AGT" people actually had better kidney health markers, not worse.

The "PheWAS" (The Wide-Net Scan)

The researchers also cast a wide net to see if this genetic change affected any other part of the body.

• Good Surprises: It seemed to lower the risk of hearing loss and sleep apnea (likely because high blood pressure damages the tiny vessels in the ear and affects breathing).
• No Major Red Flags: Aside from the potassium issue, there were no scary new side effects found across hundreds of different diseases.

The Take-Home Message

This study is like a genetic weather forecast. It predicts that a new class of drugs designed to stop the liver from making Angiotensinogen will:

1. Lower blood pressure effectively.
2. Save lives by preventing heart attacks and strokes.
3. Be safe for the liver and kidneys, with only the expected, manageable side effect of high potassium.

Why does this matter?
It gives doctors and drug companies the confidence to move forward with these new RNA drugs. Instead of waiting until 2030 for the final results, this genetic evidence suggests that these drugs are a very promising way to protect our hearts and brains for the future.

Technical Summary

1. Problem Statement

Hypertension is the leading modifiable risk factor for cardiovascular disease (CVD), yet a significant portion of patients remain undiagnosed or uncontrolled due to suboptimal adherence to daily oral medications. While the Renin-Angiotensin-Aldosterone System (RAAS) is a primary therapeutic target, existing drugs (ACE inhibitors, ARBs, MRAs, renin inhibitors) do not target angiotensinogen (AGT), the progenitor of the entire angiotensin-peptide family.

New RNA-based therapeutics (e.g., zilebesiran, IONIS-AGT-LRx) have shown promise in lowering blood pressure by inhibiting hepatic AGT synthesis. However, prior to large-scale Phase III outcome trials (such as the ongoing ZENITH trial, results expected post-2030), it is unknown whether this specific mechanism translates into reduced long-term cardiovascular risk or carries significant safety concerns (e.g., kidney injury, liver toxicity).

2. Methodology

The study employed a Drug-Target Mendelian Randomization (MR) framework to use human genetic variation as a proxy for pharmacological intervention.

• Instrument Construction:
  • Primary Instrument: Genetic variants (N=46) associated with lower circulating AGT levels (measured via Olink platform in UK Biobank, N=47,745) and lower hepatic AGT mRNA expression (eQTLs from liver tissue, N=1,183).
  • Sensitivity Instruments: Variants derived from SomaScan proteomics (Icelandic cohort, N=35,559) and hepatic eQTLs to ensure robustness.
  • Validation: Colocalization analysis confirmed a shared causal signal between hepatic AGT expression and circulating protein levels (Posterior Probability H4 = 99%).
• Study Design:
  • Two-Sample MR: Used summary statistics from large-scale Genome-Wide Association Studies (GWAS).
  • Primary Outcomes: Coronary Artery Disease (CAD), Stroke, and Heart Failure (HF).
  • Secondary Outcomes: Subtypes of CAD/Stroke/HF, imaging endophenotypes (carotid plaque, cerebral small vessel disease markers, cardiac MRI volumes), and safety endpoints (kidney/liver function, electrolytes).
  • Phenome-Wide Association Study (PheWAS): Analyzed 326 clinical outcomes across FinnGen, MVP, and UK Biobank to detect repurposing opportunities or unexpected adverse effects.
  • Comparative Analysis: Compared the efficacy of AGT inhibition against genetic proxies for other approved RAAS blockers (ACEi, ARBs, Renin inhibitors) per unit of Systolic Blood Pressure (SBP) reduction.
• Statistical Approach: Primary analysis used Inverse Variance Weighted (IVW) MR. Sensitivity analyses included MR-Egger, Weighted Median, and heterogeneity tests (Cochran's Q). Significance thresholds were adjusted for multiple comparisons (Bonferroni for primary outcomes).

3. Key Contributions

• Genetic Validation of a Novel Target: Provides the first human genetic evidence that lifelong downregulation of hepatic AGT synthesis mimics the effects of RNA-based therapies and reduces cardiovascular risk.
• Safety Profile Assessment: Systematically evaluates safety signals (specifically hyperkalemia, kidney function, and liver enzymes) prior to Phase III trial completion.
• Mechanistic Insight: Demonstrates that AGT inhibition affects not only major clinical events but also subclinical vascular pathologies (atherosclerosis, cerebral small vessel disease, and adverse cardiac remodeling).
• Comparative Efficacy: Shows that AGT inhibition is non-inferior to, and potentially broader in scope than, existing RAAS-blocking classes regarding cardiovascular protection.

4. Key Results

Physiological Effects (Positive Controls)

• Blood Pressure: Genetically proxied AGT inhibition was associated with significant reductions in SBP (-0.60 mmHg per SD reduction) and DBP (-0.40 mmHg).
• Biomarkers: Associated with increased Renin levels (expected due to negative feedback loop) and increased Potassium levels (consistent with RAAS inhibition).
• Drug Correlation: The magnitude of BP reduction per unit of AGT lowering was comparable to the effects observed in the KARDIA-1 clinical trial for zilebesiran.

Cardiovascular Outcomes

• Primary Endpoints: AGT inhibition was significantly associated with lower odds of:
  • Coronary Artery Disease (CAD): OR 0.954 per 1 mmHg SBP reduction.
  • Stroke: OR 0.949 per 1 mmHg SBP reduction.
  • Heart Failure (HF): OR 0.972 per 1 mmHg SBP reduction.
• Subtypes & Imaging:
  • Reduced risk of Myocardial Infarction, Angina, and Ischemic Stroke (including cardioembolic and small-vessel subtypes).
  • Reduced burden of Cerebral Small Vessel Disease (cSVD): Lower White Matter Hyperintensity (WMH) volume and reduced mean diffusivity.
  • Reduced Carotid Intima-Media Thickness (cIMT) and plaque presence.
  • Cardiac Remodeling: Associated with favorable changes in cardiac MRI, including reduced Left Ventricular End-Diastolic Volume (LVEDV), Mass (LVM), and mean wall thickness.

Safety Outcomes

• Hyperkalemia: Consistent association with increased blood potassium levels (a known class effect of RAAS inhibition).
• Kidney Function: No evidence of impaired kidney function; the primary instrument showed a protective association against Chronic Kidney Disease (CKD). (Note: SomaScan-based sensitivity analysis showed conflicting signals, warranting caution).
• Liver Safety: An isolated association with slightly elevated Aspartate Aminotransferase (AST) was found, but no changes in ALT, bilirubin, or other liver markers. This signal was not replicated across all instruments.

PheWAS Findings

• Repurposing Signals: Strong associations with reduced risk of hypertension, atrial fibrillation, pulmonary edema, and sensorineural hearing loss (potentially linked to microangiopathy).
• Safety Signals: No major clustering of adverse events; isolated associations with conditions like urinary retention and pneumonia were observed but lacked clear biological patterns.

5. Significance and Conclusion

This study provides robust human genetic evidence supporting the hypothesis that inhibiting hepatic angiotensinogen synthesis is a highly effective strategy for reducing the burden of cardiovascular disease.

• Clinical Implication: The results suggest that RNA-based AGT inhibitors (like zilebesiran) have the potential to reduce major adverse cardiovascular events (MACE) and slow the progression of subclinical vascular damage (both cerebral and cardiac).
• Safety: The safety profile appears favorable, with the primary concern being manageable hyperkalemia, similar to existing RAAS blockers, and no strong signal for liver or kidney toxicity.
• Strategic Value: These findings provide a strong rationale for prioritizing AGT inhibitors in cardio- and cerebrovascular outcome trials (e.g., ZENITH) and support the development of long-acting, infrequent-dosing RNA therapeutics to improve patient adherence and cardiovascular outcomes.

The study concludes that genetic downregulation of AGT synthesis is a promising therapeutic avenue that warrants further clinical validation to confirm its ability to meaningfully reduce cardiovascular risk.